Vertex Pharmaceuticals, Inc. (VRTX)
547.74
-0.31
(-0.06%)
USD |
NASDAQ |
Aug 24, 16:00
548.20
+0.46
(+0.08%)
After-Hours: 20:00
Vertex Pharmaceuticals Price to Book Value : 6.854 for Aug. 24, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 6.857 |
| August 20, 2026 | 6.760 |
| August 19, 2026 | 6.908 |
| August 18, 2026 | 6.609 |
| August 17, 2026 | 6.451 |
| August 14, 2026 | 6.328 |
| August 13, 2026 | 6.462 |
| August 12, 2026 | 6.578 |
| August 11, 2026 | 6.627 |
| August 10, 2026 | 6.555 |
| August 07, 2026 | 6.207 |
| August 06, 2026 | 6.056 |
| August 05, 2026 | 6.066 |
| August 04, 2026 | 5.990 |
| August 03, 2026 | 5.890 |
| July 31, 2026 | 5.970 |
| July 30, 2026 | 6.027 |
| July 29, 2026 | 6.048 |
| July 28, 2026 | 6.136 |
| July 27, 2026 | 5.993 |
| July 24, 2026 | 5.973 |
| July 23, 2026 | 5.919 |
| July 22, 2026 | 5.913 |
| July 21, 2026 | 6.031 |
| July 20, 2026 | 6.012 |
| Date | Value |
|---|---|
| July 17, 2026 | 6.077 |
| July 16, 2026 | 6.081 |
| July 15, 2026 | 5.969 |
| July 14, 2026 | 5.960 |
| July 13, 2026 | 6.009 |
| July 10, 2026 | 6.073 |
| July 09, 2026 | 6.212 |
| July 08, 2026 | 6.236 |
| July 07, 2026 | 6.534 |
| July 06, 2026 | 6.626 |
| July 02, 2026 | 6.607 |
| July 01, 2026 | 6.231 |
| June 30, 2026 | 6.215 |
| June 29, 2026 | 6.559 |
| June 26, 2026 | 6.450 |
| June 25, 2026 | 6.303 |
| June 24, 2026 | 6.238 |
| June 23, 2026 | 6.149 |
| June 22, 2026 | 6.128 |
| June 18, 2026 | 5.929 |
| June 17, 2026 | 6.025 |
| June 16, 2026 | 5.949 |
| June 15, 2026 | 5.913 |
| June 12, 2026 | 5.840 |
| June 11, 2026 | 5.842 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Gilead Sciences, Inc. | 15.40 |
| Alnylam Pharmaceuticals, Inc. | 23.31 |
| Regeneron Pharmaceuticals, Inc. | 2.702 |
| Sionna Therapeutics, Inc. | 0.9500 |
| Biogen, Inc. | 1.709 |
Price to Book Value Related Metrics
| PE Ratio | 31.87 |
| PS Ratio | 11.05 |
| PEG Ratio | 1.394 |
| Price to Free Cash Flow | 36.98 |
| Price | 547.74 |
| Earnings Yield | 3.14% |
| Market Cap | 138.77B |
| PEGY Ratio | 1.394 |
| Operating PE Ratio | 27.96 |
| Normalized PE Ratio | 31.02 |